 |
|
|
|
 |
|
|
| Article 1 to 10 out of 11 concerning Schering-Plough Corporation
|
-
Schering-Plough Extends Antibody Alliance with MorphoSys
(05/20/2008)
MorphoSys AG announced that Schering-Plough Corporation has decided to extend the current collaboration between the two companies for one year. The collaboration, announced in May 2006, has a maximum term of 5 years until 2011 and may be extended by ...
-
Akzo Nobel completes OBS sale
(11/21/2007)
Akzo Nobel N.V. has completed the sale of Organon BioSciences N.V. to Schering-Plough Corporation for EUR 11 billion. Confirmation of the completion of the transaction comes after Schering-Plough received all the necessary approvals, including ...
-
Pharminox and Schering-Plough to collaborate on research into novel anti-cancer agents
(12/13/2006)
Pharminox Limited announced that it has signed an agreement with the Schering-Plough Research Institute, the research arm of Schering-Plough Corporation, to undertake a joint research programme aimed at discovering novel small molecule anti-cancer ...
-
OncoMethylome Sciences Expands its Collaboration with Schering-Plough
(10/26/2006)
OncoMethylome Sciences announced that it has entered into a new non-exclusive service agreement with Schering-Plough. Under the terms of the new agreement, OncoMethylome will receive processing fees for providing Schering-Plough with testing ...
-
Codexis Achieves Development Milestone in Research Agreement with Schering-Plough
(09/13/2006)
Codexis, Inc. announced it has achieved an important development milestone under a research agreement with Schering-Plough Corporation. The objective of the collaboration with Schering-Plough is to rapidly generate a novel biocatalytic process to ...
-
Oncomethylome Sciences achieves key milestone in Schering-Plough collaboration
(08/25/2006)
OncoMethylome Sciences announced that it achieved a key milestone in its collaboration with Schering-Plough. Schering-Plough has approved OncoMethylome Sciences' sub contractor, BRT Laboratories (Maryland, USA) as a clinical trial testing facility. ...
-
Xenogen Biosciences Announces Target Validation Collaboration Agreement with Schering-Plough
(08/21/2006)
Xenogen Biosciences, acquired on August 9, 2006, by Caliper Life Sciences, Inc. , announced a target validation collaboration with Schering-Plough Corporation, under which Xenogen Biosciences will utilize its proprietary Serial Phenotyping ...
-
Schering-Plough Discontinues Phase II Study of Vicriviroc in Treatment-Naive HIV Patients
(10/31/2005)
Continues Phase II Study in Treatment-Experienced HIV Patients
Schering-Plough Corporation reported that it has discontinued a Phase II study with its investigational CCR5 receptor antagonist, vicriviroc, used in combination with Combivir in treatment-naive HIV patients. This decision was due to a return of ...
-
Ingenuity Technology Licensed by Schering-Plough Research Institute (SPRI)
(10/13/2005)
NEW Ingenuity Pathways Analysis 3.0 Deployed to SPRI Researchers
Ingenuity announced that Schering-Plough Research Institute, the global pharmaceutical research arm of Schering-Plough Corporation has licensed both Ingenuity Pathways Analysis and the Ingenuity Pathways Analysis Integration Module (IPA-IM). ...
-
Schering-Plough Appoints Paul Medeiros Vice President, Global Licensing
(08/03/2005)
Schering-Plough Corporation announced that Paul Medeiros has been appointed vice president, Global Licensing, effective immediately. He is based in Kenilworth and reports to Michael J. DuBois, senior vice president, Global Licensing.In this role, ...
|
|
|
|
|
Top